Health care resource utilization and disease modifying treatment use in multiple sclerosis patients by age and insurance type. (3rd April 2021)

• Record Type: Journal Article
• Authors: Cisternas, Miriam; Bartolome, Lauren; Gitar, Bret; Hulbert, Erin; Trenz, Helen; Patel, Vikram; Johnson, Kristen; Russo, Patricia A.
• Is Part Of: Current medical research and opinion. Volume 37:Number 4(2021)
• Page Start: 597
• Page End: 604
• Publication Date: 2021-04-03
• Subjects: Multiple sclerosis -- MS -- disease-modifying therapies -- DMT -- health care resource utilization -- retrospective claims -- commercial Medicare advantage; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2021.1885367
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: The objective of this study was to describe and compare health care resource utilization (HCRU) and disease modifying treatment (DMT) use among US adults <65 years with multiple sclerosis (MS), across commercial and Medicare Advantage plans. Methods: Medical and pharmacy claims data from commercial and Medicare Advantage with Part D (MAPD) plans were extracted for MS patients age 18 − 64 identified between 1 January 2014 and 31 May 2017. Comparisons were made between commercial and MAPD enrollees for all-cause HCRU and DMT use over 1 year, overall and by 5 year age groups. Results: A total of 28, 427 MS patients were identified; two-thirds (67%) had commercial coverage. MAPD patients had statistically significantly higher mean counts of all-cause inpatient, emergency room (ER) and ambulatory visits compared to commercial patients. The significant differences were evident in all age groups ≥30 years, except for ER visits in the 40–44 and 60–64 age groups. MAPD patients had statistically significantly lower prevalence of DMT use compared to commercial patients in all age groups starting at ≥35 years. Conclusion: MAPD patients had a higher burden of medical HCRU compared to their commercially insured counterparts, most likely due primarily to their more advanced disease state and higher level of MS-related disability. Reasons for lower prevalence of DMT use among MAPD patients may include their more advanced disease state, older age and higher prevalence of comorbid conditions compared with commercially insured patients, as well as more restrictive formularies for MAPD vs. commercial plans. These findings suggest that there may be an opportunity for recently approved DMTs indicated for active secondary progressive MS to fulfill an unmet need for treatment among MS patients <65 years without contraindicated comorbid conditions who are enrolled in MAPD plans. Novel therapies under development to delay progression may help keep MS patients of working age in the work force.